Quality Control of Platelet Concentrates by the Thrombostat 4000

1995 ◽  
Vol 21 (S 02) ◽  
pp. 91-95 ◽  
Author(s):  
Markus Böck ◽  
Joachim Groh ◽  
Anle Glaser ◽  
Klaus Storck ◽  
Michael Kratzer ◽  
...  
Keyword(s):  
Quality Control ◽  
Platelet Function ◽  
Test System ◽  
Serotonin Release ◽  
Small Sample ◽  
Platelet Concentrates ◽  
Platelet Function Tests ◽  
Special Equipment ◽  
Function Tests

Quality control of platelet concentrates (PC) is an important prerequisite for good transfusion praxis. However, direct measurement of platelet function is complex, since available methods (e.g. aggregometry, serotonin release) are time consuming and require special equipment. Therefore a test system is needed, which is easy to handle, fast, and achieves reliable results. The present paper compares the results of conventional platelet function tests with those of a modified in-vitro bleeding test (IVBT) (Thrombostat 4000) in liquid-stored and cryopreserved PCs. A high correlation between aggregometry, serotonin release, GMP 140 expression upon stimulation, and IVBT was demonstrated. Therefore IVBT seems to be a good alternative to the conventional platelet function tests for quality control of PCs. In addition, a good correlation between the results of IVBT of patients’ blood after PC transfusion and IVBT of patients blood before transfusion supplemented with platelets of the respective PC could be found. Therefore IVBT seems to be able to predict PC transfusion success. However, since these data were obtained in a small sample undergoing bone marrow transplantation, further studies are needed to verify this hypothesis.

scholarly journals Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement

2020 ◽  
Author(s):  
Diana A. Gorog ◽  
Richard C. Becker
Keyword(s):  
Platelet Aggregation ◽  
Platelet Function ◽  
Arterial Thrombosis ◽  
Point Of Care ◽  
Laboratory Research ◽  
Platelet Function Tests ◽  
Function Tests ◽  
Antiplatelet Medication ◽  
Platelet Aggregometry

Abstract Studies using whole blood platelet aggregometry as a laboratory research tool, provided important insights into the mechanism and modulators of platelet aggregation. Subsequently, a number of point-of-care (POC) platelet function tests (PFTs) were developed for clinical use, based on the concept that an individual’s thrombotic profile could be assessed in vitro by assessing the response to stimulation of platelet aggregation by specific, usually solo agonists such as adenosine diphosphate (ADP), collagen and thrombin. However, adjusting antiplatelet medication in order to improve the results of such POC PFTs has not translated into a meaningful reduction in cardiovascular events, which may be attributable to important differences between the POC PFT techniques and in vivo conditions, including patient-to-patient variability. Important limitations of most tests include the use of citrate-anticoagulated blood. Citrate directly and irreversibly diminishes platelet function and even after recalcification, it may result in altered platelet aggregation in response to ADP, epinephrine or collagen, and interfere with thrombin generation from activated platelets. Furthermore, most tests do not employ flowing blood and therefore do not assess the effect of high shear forces on platelets that initiate, propagate and stabilize arterial thrombi. Finally, the effect of endogenous thrombolysis, due to fibrinolysis and dislodgement, which ultimately determines the outcome of a thrombotic stimulus, is mostly not assessed. In order to accurately reflect an individual’s predisposition to arterial thrombosis, future tests of thrombotic status which overcome these limitations should be used, to improve cardiovascular risk prediction and to guide pharmacotherapy.

The Activity Of PhthalazinoL In Basic Platelet Function Tests

1981 ◽  
Author(s):  
R N Saunders ◽  
S L Smith ◽  
N S Nicholson
Keyword(s):  
Platelet Function ◽  
Ex Vivo ◽  
Platelet Function Tests ◽  
Antithrombotic Agent ◽  
Serotonin Content ◽  
Positive Effects ◽  
Arterial Blood ◽  
Function Tests ◽  
Induced Aggregation

Phthalazinol (EG-626, SC-32840) was evaluated in several basic platelet function tests in comparison with known antiplatelet agents. The IC50șs for collagen-, ADP-, and thrombin-induced aggregation of human platelets in vitro were 28, 51 and 88 µM, respectively. Phthalazinol (100 µM) did not alter the cAMP levels of rat platelets in vitro in either the presence or absence of PGE1. When administered orally to retired breeder rats, Phthalazinol prevented the formation of platelet aggregates as determined by the Wu and Hoak technique with ED50’s of 5.5 and 18.7 mpk, i.g. at 3 and 24 hours, respectively, post injection. Phthalazinol did not alter the platelet serotonin content in rats even when administered at 100 mg/kg orally for three days. In an ex vivo disaggregation assay, arterial blood from anesthetized cats was perfused over rabbit tendon strips and recirculated to the cat. The resulting platelet build-up (200-400 mg) was significantly (p < .001) reversed (67% loss) by the i.v. infusion of Phthalazinol at 15 mg/kg. Phthalazinol has demonstrated positive effects in several platelet evaluation models and is a potentially unique antithrombotic agent.

In Vitro Dose Response to Different GPIIb/IIIa-Antagonists: Inter-Laboratory Comparison of Various Platelet Function Tests

2001 ◽  
Vol 102 (1) ◽  
pp. 39-48 ◽  
Author(s):  
S Harder ◽  
U Klinkhardt ◽  
J Graff ◽  
D Westrup ◽  
C.M Kirchmaier ◽  
...  
Keyword(s):  
Platelet Function ◽  
Dose Response ◽  
Platelet Function Tests ◽  
Function Tests

scholarly journals Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition

2019 ◽  
Vol 50 (1) ◽  
pp. 135-143 ◽  
Author(s):  
Joao D. Dias ◽  
Torben Pottgiesser ◽  
Jan Hartmann ◽  
Daniel Duerschmied ◽  
Christoph Bode ◽  
...  
Keyword(s):  
Platelet Function ◽  
Whole Blood ◽  
Linear Models ◽  
Point Of Care ◽  
Platelet Function Tests ◽  
Blood Samples ◽  
P2y12 Inhibitors ◽  
Function Tests ◽  
Increased Risk

Abstract In the context of interventional cardiology, platelet function testing may identify patients treated with P2Y12-inhibitors at an increased risk of mortality, thrombosis and bleeding. Several whole blood point-of-care platelet function analyzers are available; however, inter-device differences have not been examined systematically. To compare three platelet function tests under standardized in vitro conditions. Healthy volunteer (n = 10) blood samples were spiked with increasing concentrations of ticagrelor (0–7500 ng/mL) and/or ASA (0–3280 ng/mL), measured on three platelet function analyzers (TEG®6s, Multiplate®, and VerifyNow®) and respective Effective Concentration (EC) levels EC10, EC50 and EC90 were calculated. Repeatability was assessed in a separate group of pooled blood samples (n = 10) spiked with ticagrelor at EC10, EC50 and EC90. ASA had no impact on ADP-activated channels for all three devices. TEG®6s was able to distinguish (p ≤ 0.05) between all ticagrelor EC zones; VerifyNow® and Multiplate® were able to distinguish between three and two zones, respectively. Multiplate® showed the largest window between EC10 and EC90 (19–9153 ng/mL), followed by TEG®6s (144–2589 ng/mL), and VerifyNow® (191–1100 ng/mL). Drug effect models distribution of disagreements were identified for TEG®6s (5.0%), VerifyNow® (8.3%), and Multiplate® (13.3%). TEG®6s showed the smallest average coefficient of variation between EC conditions (5.1%), followed by Multiplate® (14.1%), and VerifyNow® (17.7%). Linear models could be generated between TEG®6s and Multiplate®, but not VerifyNow®. Significant differences were found between whole blood point-of-care platelet function analyzers and the clinical impact of these differences needs to be further investigated.

Sign in / Sign up

Export Citation Format

Share Document